Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Investigating the Effect of Digesta-Lac in Healthy Adults With Occasional Constipation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02423564
Recruitment Status : Completed
First Posted : April 22, 2015
Last Update Posted : April 11, 2018
Sponsor:
Collaborator:
Global Institute of Probiotics
Information provided by (Responsible Party):
KGK Science Inc.

Brief Summary:
This investigation will evaluate the effect of Digesta-Lac in adults with occasional constipation in a single-center, randomized, double-blind, placebo-controlled, parallel group 2-arm study for 3 weeks.

Condition or disease Intervention/treatment Phase
Occasional Constipation Dietary Supplement: Digesta Lac Other: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 54 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Other
Official Title: A Double-blind, Placebo-controlled, Parallel Study Investigating the Effect of Digesta-Lac in Healthy Adults With Occasional Constipation
Actual Study Start Date : June 12, 2015
Actual Primary Completion Date : April 12, 2016
Actual Study Completion Date : May 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Constipation

Arm Intervention/treatment
Active Comparator: Healthy Population with Digesta Lac
Digesta Lac is Lactobacillus bulgaricus LB-51 at 2.0 billion cfu with non-medicinal ingredients: cellulose, potato powder, chick pea extract, vitamin c, L-leucine, vegetable capsule (hypromellose)
Dietary Supplement: Digesta Lac
Placebo Comparator: Healthy Population with Placebo
Placebo contains: cellulose, Organic Whole Grain Brown Rice Milk Concentrate, L-Leucine, potato powder, vegetable capsule (hypromellose)
Other: Placebo



Primary Outcome Measures :
  1. Mean difference (probiotic - placebo) in the number of weekly complete spontaneous bowel movements [ Time Frame: Baseline to Day 21 ]

Secondary Outcome Measures :
  1. The between group difference in the average number of weekly complete spontaneous bowel movements [ Time Frame: Baseline to Day 21 ]
  2. The percentage of responders vs. non- responders for the average number of weekly complete spontaneous bowel movements [ Time Frame: Day 21 ]
  3. The mean difference (probiotic - placebo) in the number of weekly spontaneous bowel movements [ Time Frame: Baseline to Day 21 ]
  4. The between group difference in the average number of weekly spontaneous bowel movements [ Time Frame: Baseline to Day 21 ]
  5. The percentage of responders vs. non- responders for the average number of weekly spontaneous bowel movements [ Time Frame: Day 21 ]
  6. The mean difference (probiotic - placebo) in the number of weekly bowel movements [ Time Frame: Baseline to Day 21 ]
  7. The between group difference in the average number of weekly bowel movements [ Time Frame: Baseline to Day 21 ]
  8. The percentage of responders vs. non- responders for the average number of weekly bowel movements [ Time Frame: Day 21 ]
  9. Changes in bowel habits (straining, feeling of complete evacuation) as assessed by the daily bowel habits diary [ Time Frame: Baseline to Day 21 ]
  10. Change in Bristol Stool Score [ Time Frame: Baseline to Day 21 ]
  11. Change in symptoms related to constipation determined by the Gastrointestinal Symptom Rating Scale [ Time Frame: Baseline to Day 21 ]
  12. Mean score of the Product Perception Questionnaire [ Time Frame: Day 21 ]
  13. The between group difference in the percentage of subjects that used a laxative [ Time Frame: Baseline to Day 21 ]
  14. The between group difference in the total number of days per subject that a laxative [ Time Frame: Baseline to Day 21 ]

Other Outcome Measures:
  1. Laboratory parameters of safety - CBC [ Time Frame: Screening to Day 21 ]
  2. Laboratory parameters of safety - Electrolytes [ Time Frame: Screening to Day 21 ]
  3. Laboratory parameters of safety - Kidney function markers [ Time Frame: Screening to Day 21 ]
  4. Laboratory parameters of safety - Liver function markers [ Time Frame: Screening to Day 21 ]
  5. Anthropometric measures - Weight [ Time Frame: Screening to Day 21 ]
  6. Anthropometric measures - BMI [ Time Frame: Screening to Day 21 ]
  7. Anthropometric measures - Blood Pressure [ Time Frame: Screening to Day 21 ]
  8. Anthropometric measures - Heart Rate [ Time Frame: Screening to Day 21 ]
  9. Incidence of Adverse Events [ Time Frame: Baseline to Day 21 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male or female between 18-65 years of age (inclusive)
  • If female, subject is not of child bearing potential. Defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with > 1 year since last menstruation).

OR Female subject of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. Acceptable methods of birth control include: Double barrier method, Hormonal contraceptives (including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)), Intrauterine devices, Vasectomy of partner, Non-heterosexual lifestyle

  • BMI 18.5-35.0kg/m2
  • Subjects must have < 3 bowel movements per week for at least 2 weeks (but for not more than 12 weeks in the past 6 months) prior to randomization (confirmed at screening and baseline) and the presence of at least one other bowel symptom of constipation in at least 25% of defecations; Hard stools. or complete lack of loose or watery stools, straining during defecation, feelings of incomplete evacuation, abdominal discomfort, bloating/distension
  • Healthy as determined by laboratory results, medical history and physical exam
  • Subjects must agree not to use any other products or therapies (i.e. enemas) to treat their constipation during the run-in to the study (7 days prior to baseline) or during the course of the study except as a rescue medication.
  • Agrees not to change current dietary habits (with the exception of avoiding pro- and prebiotics), smoking habits and activity/training levels one week prior to randomization and during the course of the study
  • Has given voluntary, written, informed consent to participate in the study

Exclusion Criteria:

  • Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial
  • Subjects currently under a doctor's care and treatment for constipation
  • Subjects that have a history of chronic constipation(defined as <3 bowel movements per week for more than 3 months) due to any underlying cause (IBS, functional constipation [chronic constipation], IBD, ulcer, etc.) based on self-report, physical examination, or documented medical history
  • Subjects who have severe abdominal pain as the predominant constipation symptom as determined by the Principal Investigator.
  • Subjects who have a history of colorectal cancer, anal abscess, anal fistula, anal fissure, anal stenosis, gastric retention or obstruction, bowel resection, rectocele, colostomy, IBS, Crohn's disease, episiotomy or hemorrhoids.
  • Subjects with a history of spinal injuries and/or surgeries which could result in an atonic colon or saddle anesthesia (i.e. spinal fusion in the lumbar spine)
  • Subjects who have been hospitalized within the past 3 months
  • Subjects with known renal or hepatic insufficiency
  • Subjects with gastrointestinal bleeding or acute infection
  • Subjects who use prescription medication to treat constipation
  • Subjects who have previously suffered from slipped discs
  • Subjects who plan to use OTC laxatives or stool softeners, or any other products meant to treat constipation other than the study supplements, during the treatment period (use as a rescue medication is permitted) or other therapies such as enemas.
  • Subjects currently taking or taken within 28 days of randomization a concomitant medication that causes constipation which in the Principle Investigator's opinion may impact the study results.
  • Any non-gastrointestinal disease/complication that, in the investigator's opinion, may affect subject safety or confound the evaluation of the study endpoints
  • Immunodeficiency (i.e. HIV positive, rheumatoid arthritis, history of organ transplant)
  • Clinically significant abnormal laboratory results at screening (e.g. AST and/or ALT > 2 x ULN, and/or bilirubin > 2 x ULN; serum creatinine > 1.5 x ULN; hemoglobin < 140 g/L for males and < 123 g/L for females)
  • Abdominal or perineal surgery within 6 months of randomization
  • Subjects who plan on engaging in anal intercourse during the run-in or treatment periods of the trial. Enemas are not allowed within 7 days of randomization or throughout the trial.
  • Participation in a clinical research trial within 30 days prior to randomization or participation in a clinical trial researching a probiotic within 60 days prior to randomization
  • Currently taking anti-psychotic medication
  • Allergy or sensitivity to study supplement ingredients
  • Use of pre- and probiotics within 8 weeks prior to randomization
  • Alcohol abuse (>2 standard alcoholic drinks per day) or drug abuse within the past 6 months
  • Individuals who are cognitively impaired and/or who are unable to give informed consent.
  • Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02423564


Locations
Layout table for location information
Canada, Ontario
KGK Synergize Inc.
London, Ontario, Canada, N6A 5R8
Sponsors and Collaborators
KGK Science Inc.
Global Institute of Probiotics
Investigators
Layout table for investigator information
Principal Investigator: Tetyana Pelipyagina, MD KGK Science Inc.
Layout table for additonal information
Responsible Party: KGK Science Inc.
ClinicalTrials.gov Identifier: NCT02423564    
Other Study ID Numbers: 14PCHN
First Posted: April 22, 2015    Key Record Dates
Last Update Posted: April 11, 2018
Last Verified: April 2018
Keywords provided by KGK Science Inc.:
Probiotic
Digesta-Lac
Occasional Constipation
Constipation
Additional relevant MeSH terms:
Layout table for MeSH terms
Constipation
Signs and Symptoms, Digestive